Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0826, ertapenem · 2 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| MK0826, ertapenem sodium | DRUG | - |
| Comparator: cefotetan | DRUG | - |
| Comparator: Ticarcillin/Clavulanate | DRUG | - |
Inclusion Criteria: Male or female patients 18 years of age scheduled to undergo elective colon or colorectal surgery by laparotomy must meet the following criteria: * Surgery must be scheduled in advance. * There must be adequate time to complete preoperative bowel preparation
MK0826, also known as ertapenem, is an investigational small molecule being studied for the treatment of colorectal surgery infections, complicated intra-abdominal infections, and intra-abdominal infections. It is in Phase 3 clinical development for these gastrointestinal indications.
MK0826, also known as ertapenem, is a carbapenem antibiotic that targets bacterial cell wall synthesis. It is being studied for its effectiveness against infections following colorectal surgery and complicated intra-abdominal infections.
MK0826, also known as ertapenem, is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug for the treatment of intra-abdominal infections.
MK0826, also known as ertapenem, is in Phase 3 clinical development. It is an investigational drug and has not been approved for the indications being studied, including colorectal surgery infections and complicated intra-abdominal infections.
MK0826, also known as ertapenem, has completed several clinical trials. These include NCT00090272, a Phase 3 study in colorectal surgery with 952 participants, and NCT00389987, a Phase 3 study in complicated intra-abdominal infections with 300 participants.
Yes, MK0826 is the same as ertapenem. The drug is referred to by both names in clinical trials, including studies NCT00090272 and NCT00389987, which evaluate ertapenem for the treatment of intra-abdominal infections.